Home / Intelligence / Blog / Developing Effective Global Value Dossiers
Published June 13, 2024
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.
Understanding the Challenge
The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level of detail and more. Regional affiliates were also interviewed to understand what they liked and what they found challenging about the GVDs.
Identifying Key Areas for Improvement
The team discovered that while the mechanics of GVD creation were usually well done, affiliates struggled to find the regional data most relevant to them and GVDs did not always help users see the strategic thread between different sections.
Developing a GVD Best Practice Toolkit
To address these challenges, Trinity developed a GVD best practice toolkit that provided guidance on how to write each chapter of the GVD. The toolkit also included several checklists and practical tools. These included a schematic showing what each stakeholder in the cross-functional team was responsible for and by when, as well as a mapping of drivers and evidence requirements for each country and checklists for each stage of the process.
Overcoming Challenges in GVD Development
Our analysis of GVDs across many therapy areas found that one challenge that teams frequently encounter is presenting a cogent economic story that aligns with the overall strategic goals of the GVD while also being practical and tactical.
The process developed by Trinity was designed to flex to different needs in different markets while maintaining consistency in how evidence is portrayed and messaged.
Conclusion and Call to Action
Overall, the project demonstrated the value of taking an independent view of GVD development and incorporating feedback from regional affiliates to create a more effective and streamlined process. If your company needs help with GVD development, Trinity’s Value Center of Excellence can provide guidance and support. Contact us to learn more.
Meet Our Experts
Related Intelligence
Blog
Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or […]
Read More
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More